Cryptococcosis

Cryptococcosis is an infection caused by fungi in the Cryptococcus group, usually acquired by inhaling fungal cells or spores from the environment. It most often affects the lungs, but it can spread to the brain and other organs, especially in people with weakened immune systems. This spread is sometimes called disseminated cryptococcosis. Cats and other animals can also develop cryptococcosis after environmental exposure.

Cryptococcus neoformans and Cryptococcus gattii are environmental yeasts that can cause cryptococcosis disease. People usually become infected by inhaling fungal cells or spores from soil, dust, decaying wood, or material contaminated with bird droppings. The infection may remain in the lungs or spread through the bloodstream to the brain, skin, bones, or other organs.

Cryptococcosis can also occur in people who appear otherwise healthy, particularly with Cryptococcus gattii in some geographic regions. Cats may be at increased risk after environmental exposure, even though they do not necessarily have the same immune conditions associated with human disease. These risk factors do not mean that infection will definitely occur.

Clinicians combine a person’s medical history, immune status, symptoms, physical examination, and imaging, such as a chest X-ray or CT scan, with laboratory testing. Tests may include cryptococcal antigen testing, fungal culture, and microscopy. Depending on the symptoms, samples may be taken from blood, respiratory secretions, skin lesions, or cerebrospinal fluid to look for infection and determine whether it has spread.

Checking for brain or disseminated infection

Treatment uses prescription antifungal medicines and depends on whether cryptococcosis is limited to the lungs or involves the brain or other organs. Oral fluconazole may be used for selected mild or localized disease. Severe infection or central nervous system disease is often treated with combination induction therapy using liposomal amphotericin B plus flucytosine, followed by a longer treatment plan; the medical team chooses the regimen and duration according to the individual situation.

There is no widely available vaccine or guaranteed way to prevent environmental exposure to Cryptococcus. Routine screening is not recommended for the general population. People with advanced HIV or other major immune suppression should follow their clinician’s monitoring and preventive-care plan.

Localized cryptococcosis may respond well to treatment, while meningitis and disseminated cryptococcosis are more serious and may require prolonged therapy and close monitoring. Outcomes are influenced by immune status, how early the infection is diagnosed, which organs are involved, adherence to treatment, and whether complications develop. Follow-up is important because symptoms may return even after initial improvement.